跳转至内容
Merck
CN
所有图片(1)

文件

安全信息

1200000

USP

地高辛

United States Pharmacopeia (USP) Reference Standard

登录查看公司和协议定价
所有图片(1)
别名:
异羟基洋地黄毒苷
经验公式（希尔记法）:
C41H64O14
CAS号:
20830-75-5
分子量:
780.94
Beilstein:
77011
EC 号:
244-068-1
MDL编号:
MFCD00003674
UNSPSC代码:
41116107
PubChem化学物质编号:
329749590
NACRES:
NA.24

等级

pharmaceutical primary standard

API类

digoxin

制造商/商品名称

USP

应用

pharmaceutical (small molecule)

格式

neat

SMILES字符串

C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]2[C@@H](O)C[C@@H](O[C@@H]2C)O[C@H]3[C@@H](O)C[C@@H](O[C@@H]3C)O[C@H]4CC[C@@]5(C)[C@H](CC[C@@H]6[C@@H]5C[C@@H](O)[C@]7(C)[C@H](CC[C@]67O)C8=CC(=O)OC8)C4

InChI

1S/C41H64O14/c1-19-36(47)28(42)15-34(50-19)54-38-21(3)52-35(17-30(38)44)55-37-20(2)51-33(16-29(37)43)53-24-8-10-39(4)23(13-24)6-7-26-27(39)14-31(45)40(5)25(9-11-41(26,40)48)22-12-32(46)49-18-22/h12,19-21,23-31,33-38,42-45,47-48H,6-11,13-18H2,1-5H3/t19-,20-,21-,23-,24+,25-,26-,27+,28+,29+,30+,31-,33+,34+,35+,36-,37-,38-,39+,40+,41+/m1/s1

InChI key

LTMHDMANZUZIPE-PUGKRICDSA-N

基因信息

human ... ATP1A1(476) , ATP1A2(477) , ATP1A3(478) , ATP1A4(480) , ATP1B1(481) , ATP1B2(482) , ATP1B3(483) , FXYD2(486)

正在寻找类似产品? 访问 产品对比指南

相关类别

一般描述

本产品按照发行药典的发行和规定提供。支持本产品的所有信息，包括安全数据表和任何产品信息传单，都是在发行药典的授权下开发和发布的。如需进一步信息和支持，请访问现行药典网站。

应用

地高辛USP参考标准品设计用于USP规定的指定质量测试和检测。

生化/生理作用

一种强心苷，P-糖蛋白的底物，上调 Pgp 表达和下调 SXR（固醇类异生物受体）。

分析说明

这些产品仅供测试和化验使用。它们不适用于人类或动物，也不能用于诊断、治疗或治愈任何类型的疾病。

其他说明

可能适用相应的销售限制。

象形图

Skull and crossbonesHealth hazard
GHS06,GHS08

警示用语：

Danger

危险声明

H300,H331,H373

危险分类

Acute Tox. 2 Oral - Acute Tox. 3 Inhalation - STOT RE 2

WGK

WGK 3

法规信息

危险化学品

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Chang Gong et al.
Cancer research, 74(16), 4341-4352 (2014-07-02)
Phyllodes tumors of breast, even histologically diagnosed as benign, can recur locally and have metastatic potential. Histologic markers only have limited value in predicting the clinical behavior of phyllodes tumors. It remains unknown what drives the malignant progression of phyllodes
Judy W M Cheng et al.
The American journal of geriatric pharmacotherapy, 8(5), 419-427 (2011-02-22)
Digoxin has been reported to improve symptoms and reduce hospitalization in patients with heart failure as well as to control rapid ventricular rate in patients with atrial fibrillation. Both of these are high-prevalence diseases in the elderly, and yet studies
Robert J DiDomenico et al.
Pharmacotherapy, 34(11), 1121-1131 (2014-08-29)
To compare the frequency of achieving a therapeutic serum digoxin concentration (SDC), defined as 0.5-0.9 ng/ml, by using a simplified nomogram to individualize digoxin dosing with standard dosing practices in patients with heart failure, and to characterize the relationship between
Susanne Johansson et al.
Clinical pharmacokinetics, 53(9), 837-847 (2014-08-15)
Vandetanib is a selective inhibitor of vascular endothelial growth factor receptor (VEGFR), epidermal growth factor receptor (EGFR) and rearranged during transfection (RET) signalling, indicated for the treatment of medullary thyroid cancer. We investigated potential drug-drug interactions between vandetanib and metformin
Tatsushi Kodama et al.
Cancer chemotherapy and pharmacology, 74(5), 1023-1028 (2014-09-11)
The clinical efficacy of the anaplastic lymphoma kinase (ALK) inhibitor crizotinib has been demonstrated in ALK fusion-positive non-small cell lung cancer (NSCLC); however, brain metastases are frequent sites of initial failure in patients due to poor penetration of the central
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门